

## **Calendar of corporate events for fiscal year 2018**

Milan (Italy), January 30th 2018 – MolMed S.p.A. (MLMD.MI), medical biotechnology company focused on research, development, manufacturing and clinical validation of innovative therapies to treat cancer, announces the calendar of corporate events for fiscal year 2018.

The calendar is available on MolMed's website ([www.molmed.com](http://www.molmed.com)). Any amendments will be promptly communicated to the market.

### **Board of Directors**

DATE	SUBJECT
9 March 2018	Approval of draft statutory financial statements for FY 2017
11 May 2018	Approval of interim financial report at 31/03/2018 (*)
30 July 2018	Approval of half-year financial report at 30/06/2018
12 November 2018	Approval of interim financial report at 30/09/2018 (*)

(\*) additional interim financial information

### **Shareholders' Meetings**

DATE	SUBJECT
12 April 2018	Approval of statutory financial statements for FY 2017

Under the regulations in force<sup>1</sup> and in order to ensure continuity with the past, MolMed decided to continue the publication of quarterly reports as additional interim financial information ("Additional Info"), on a voluntary basis and until otherwise decided, as already done during fiscal year 2016 and 2017, with the same form and content to those of the previous fiscal years.

The Additional Info will be subject to approval by the Board of Directors (the "Board") in meetings to be held within 45 days from the end of the first and third quarter of each fiscal year, and will be disclosed to the market, again within 45 days from the end of the first and third quarter of each fiscal year, by means of:

- issuance of a press release upon the conclusion of the Board meeting approving the interim financial information;
- publication of the Additional Info on the corporate website ([www.molmed.com](http://www.molmed.com)) within the section devoted to financial reports.

<sup>1</sup> Italian Legislative Decree n. 25/2016 implementing Directive 2013/50/EU (the "Decree") eliminated the mandatory requirement to publish the quarterly interim financial reports, previously requested pursuant to paragraph 5, art.154-ter of Italian Legislative Decree n. 58/1998 (the "TUF"). The Decree also granted to Consob the powers of providing for any additional disclosure requirements beyond the annual and halfyear financial statements. On the basis of the powers granted by the Decree, Consob - by way of resolution n. 19770 of October 26, 2016 - introduced some amendments to the Issuers' Regulation concerning additional interim financial information (new Article 82-ter), in force from January 2, 2017.



PRESS RELEASE

### *About MolMed*

MolMed S.p.A. is a biotechnology company focused on research, development, manufacturing and clinical validation of innovative anticancer therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis® received Orphan Drug Designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorisation by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy at the end of 2017 and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the company is developing a therapy based on Chimeric Antigen Receptor (CAR), specifically the CAR-T CD44v6, an immune gene therapy project, currently in advanced preclinical development, potentially effective for hematological malignancies and several solid epithelial tumours. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, a GSK gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the framework of innovative anticancer therapies, MolMed's pipeline also includes NGR-hTNF, a novel therapeutic agent for solid tumours investigated in a broad clinical programme, involving more than 1,000 treated patients. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

### *For further information:*

#### **Ilaria Candotti**

##### ***Investor Relations & Communication Manager***

MolMed S.p.A.

phone: +39 02 21277.205

e-mail: [investor.relations@molmed.com](mailto:investor.relations@molmed.com)

#### **Federico Ferrari**

##### ***Press agent***

SEC Relazioni Pubbliche e Istituzionali s.r.l.

phone: +39 02 6249991

mobile +39 347 6456873

e-mail: [ferrari@secrp.it](mailto:ferrari@secrp.it)

**FROM GENES TO THERAPY**

---